Published : 20 Oct 2025
An innovative ASX-Listed Pharma from Australia, with Marketed Povidone-Iodine Antiseptic Nasal Spray has appointed Aagami to help out-license their product in India and other emerging markets.
The product has demonstrated effectiveness against cold, flu and nasal congestion. This innovative solution is currently available in Singapore since June 2024 and presently undergoing regulatory registration in the Philippines and other markets in Southeast Asia.
Commercial Availability
The product is open for in-licensing, distribution and commercialisation in additional regions, providing an opportunity for companies interested in expanding their OTC/Consumer wellness portfolio.
About our New Client
The company is dedicated to developing a range of innovative over-the-counter (OTC) products utilising the well-established antiseptic properties of povidone-iodine.
The Product: Nasal Spray
It is designed to eliminate all respiratory viruses and bacteria, without the risk of resistance. Its formulation contains 0.5% povidone-iodine, specifically crafted for safe and effective nasal administration.
Intellectual Property Protection
The product’s IP is secured through three international patent families, covering its formulation, therapeutic application for common cold, and its role in reducing viral shedding among patients with SARS-CoV-2 (COVID-19), plus trade secrets and manufacturing know-how.
Clinical Development
Successfully completed Phase 1, 2 and 3 clinical trials, demonstrating both safety and efficacy in treating colds and flu.
Commercial Status
Singapore: Since June 2024, Product is being sold in Singapore, where the Health Sciences Authority (HSA) classifies it as a topical antiseptic for nasal use.
The product is marketed to healthcare professionals, hospitals, and retail pharmacy outlets as a treatment and preventive option for the common cold and other respiratory illnesses.
· HCP promotion started in November 2024.
· 9 out of 10 HCPs support the product.
· Bought by all government hospitals
· Retail sales started in Guardian pharmacy chain in January 2025. The product won the ‘Best Newcomer’ award (cough & cold category)
Philippines: Local manufacturing of the product is underway, and an expedited registration process is underway, reflecting a regulatory pathway similar to Singapore. Registration has also been applied for in two other undisclosed Southeast Asian markets.
Regulatory:
The nasal spray has obtained a Free Sale Certificate (FSC), and the company anticipates the availability of a Certificate of Pharmaceutical Product (COPP) in the near future.
These certifications are expected to facilitate expedited registration in multiple countries. The company maintains a comprehensive registration dossier for the product. The company generally licenses the local manufacturing of the Nasal Spray to partners to facilitate registration and ensure low cost of goods.
Product Portfolio Expansion
Preparing to launch additional products in 2026, which will offer partners a broader portfolio to address medical needs in hospitals, general practice settings, and for consumers.
The client also announced that its second product- a Throat Spray. This will be launched in Singapore in mid-2026 by its licensing partner. Like the Nasal Spray, it can be sold as an antiseptic and does not require local regulatory approval.
The inventor is also the creator of Betadine Throat Gargle.
Partnership Opportunities
We invite partnership discussions in all markets such as India (except Singapore, Brunei, Malaysia and the Philippines where partnering is already done).
Aagami is excited to support the client secure Out-Licensing/Supply and distribution partnerships.
If you would like to know more, please contact:
Akshay Bavaria
Associate Director
Email: contact@aagami.com